氧化锆全膝关节置换术与相同钴铬设计的十二年结局比较:来自澳大利亚骨科协会国家关节置换登记处的17,577例假体分析
基于澳大利亚国家关节置换登记处1999年9月1日至2013年12月31日的数据,比较17,577例骨水泥型Genesis-II后交叉韧带保留型全膝关节置换术(11,608例钴铬股骨组件 vs 5,969例氧化锆股骨组件)的翻修结局。氧化锆组件在所有年龄组的所有原因翻修风险上与钴铬无显著差异(HR=0.92,95%CI 0.92-1.29,p=0.329),但≥75岁患者中氧化锆组件因松动或骨溶解的翻修率更高(p=0.033)。12年累积翻修百分比氧化锆组为7.7%(95%CI 6.2%-9.5%),高于钴铬组的4.8%(95%CI 4.2%-5.4%)。
要点
- 氧化锆与钴铬股骨组件在全因翻修风险上无显著差异(HR=0.92,95%CI 0.92-1.29,p=0.329)。
- ≥75岁患者中氧化锆组件因松动或骨溶解的翻修率更高(p=0.033)。
- 12年累积翻修百分比氧化锆组7.7%(95%CI 6.2%-9.5%)高于钴铬组4.8%(95%CI 4.2%-5.4%)。
核心结论
- 在相同假体设计的队列中,氧化锆股骨组件在所有年龄组(包括<55岁患者)中未降低全因、松动或骨溶解、或去除感染原因后的翻修率。
- 氧化锆组累积翻修百分比高于钴铬组。
研究设计与样本
- 队列研究,使用澳大利亚国家关节置换登记处数据,纳入1999年9月1日至2013年12月31日在澳大利亚实施的骨水泥型Genesis-II后交叉韧带保留型全膝关节置换术17,577例(钴铬股骨组件11,608例,氧化锆股骨组件5,969例),均使用非交联聚乙烯。
- 估计累积翻修百分比和翻修风险的危险比(HR),并检查翻修诊断以及年龄和髌骨表面置换的影响。
- 证据等级:治疗性III级。
主要发现
- 氧化锆组与钴铬组在全因翻修风险上无显著差异(HR=0.92,95%CI 0.92-1.29,p=0.329)。
- 除≥75岁患者松动或骨溶解外,松动或骨溶解及无菌性原因翻修风险无显著差异;≥75岁患者中氧化锆股骨组件全膝关节置换术翻修率更高(p=0.033)。
- 年轻患者更倾向于接受氧化锆股骨组件。
- 髌骨表面置换与否未影响翻修风险。
- 12年累积翻修百分比:钴铬Genesis-II假体4.8%(95%CI 4.2%-5.4%),氧化锆Genesis-II假体7.7%(95%CI 6.2%-9.5%)。
关键数值与推荐
- 全因翻修风险HR=0.92(95%CI 0.92-1.29),p=0.329。
- ≥75岁患者松动或骨溶解翻修p=0.033。
- 12年累积翻修百分比:钴铬组4.8%(95%CI 4.2%-5.4%) vs 氧化锆组7.7%(95%CI 6.2%-9.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oxidized zirconium (Oxinium) was introduced as an alternative bearing surface to cobalt-chromium (CoCr) in an attempt to reduce polyethylene wear and decrease aseptic mechanical failure of total knee replacements. While noncomparative reports have been described as promising, we were aware of no short or long-term clinical studies showing the superiority of Oxinium on polyethylene as a bearing surface. Using data from a comprehensive national joint replacement registry, we compared the long-term outcomes after cruciate-retaining total knee arthroplasty (TKA) with an Oxinium femoral component and those with the same prosthetic design but with a CoCr femoral component. METHODS: The cohorts consisted of 17,577 cemented Genesis-II cruciate-retaining total knee replacements using non-cross-linked polyethylene, which included 11,608 with CoCr femoral components and 5,969 with Oxinium femoral components. The cumulative percent revision and hazard ratio (HR) for revision risk were estimated for the cemented Genesis-II Oxinium and CoCr cruciate-retaining TKAs performed in Australia from September 1, 1999, to December 31, 2013. In addition, the revision diagnoses and the effects of age and patellar resurfacing were examined. RESULTS: No difference in the HR for revision risk was found between the Oxinium and CoCr cohorts for any age category for all causes of revision (HR = 0.92 [95% confidence interval (CI), 0.92 to 1.29]; p = 0.329), loosening or lysis, or aseptic causes, except for loosening or lysis in the group of patients who were ≥75 years old (p = 0.033). In these patients, TKA with Oxinium femoral components had a higher rate of revision. Younger patients preferentially received Oxinium femoral components. The revision risk was not affected by patellar resurfacing or nonresurfacing. At 12 years, the cumulative percent revision was 4.8% (95% CI, 4.2% to 5.4%) for the CoCr Genesis-II prosthesis compared with 7.7% (95% CI, 6.2% to 9.5%) for the Oxinium Genesis-II prosthesis. CONCLUSIONS: In this cohort study involving the same prosthetic design, Oxinium femoral components did not reduce revision rates for all causes, loosening or lysis, or when infection as a cause of revision was removed compared with the same CoCr femoral component across all age groups including patients who were <55 years old. The cumulative percent revision was greater for the Oxinium components than for the CoCr components. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Vertullo CJ, Lewis PL, Graves S, et al. Twelve-Year Outcomes of an Oxinium Total Knee Replacement Compared with the Same Cobalt-Chromium Design: An Analysis of 17,577 Prostheses from the Australian Orthopaedic Association National Joint Replacement Registry. J Bone Joint Surg Am. 2017. PMID: 28196029. doi:10.2106/JBJS.16.00092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。